Braveheart on investors' radar as coronavirus shines light on portfolio
Last updated: 07:38 06 Mar 2024 GMT, First published: 11:19 01 Dec 2022 GMT
Snapshot
- Braveheart ups stake in car acoustics firm Autins
- Braveheart Investment Group’s subsidiary Paraytec present their Covid-19 test
About the company
Braveheart Investment Group makes strategic investments in companies it judges will outperform.
Along with financial investment the group also provides expert advice to the companies it backs and helps them make decisions around operations, strategy and risk.
Its aim is to return cash to shareholders while increasing the value of the shares.
How it is doing
Braveheart Investment Group PLC (AIM:BRH) has put more money into Autins Group PLC (AIM:AUTG), lifting its stake to 23.42%.
Some four million shares were bought between Monday and Tuesday, Braveheart said in a statement on Wednesday.
This was at an average price of 8p per share, representing a total investment of £320,000.
Austin’s, which specialises in solving acoustic and thermal products for the automotive industry, is listed on AIM.
Braveheart Investment Group PLC (AIM:BRH) announced it has completed the sale of Phasefocus, the medical imaging company.
Bruker UK paid around £2.1 million for the business, having met all the conditions of the deal.
Shares in Braveheart jumped 6% as it confirmed another company in its portfolio was changing hands.
Last week, the investment company put its Paraytec diagnostics business up for sale.
What management says
Braveheart Investment Group’s subsidiary Paraytec is working on developing a more accurate, efficient and low cost Covid-19 test, in collaboration with the University of Sheffield.
In this short video, made by the University, Viv Hallam (COO for Braveheart Investment Group) provides an introduction, with Professor Carl Smythe and his team describing how Paraytec’s COVID-19 test works.